US OptionsDetailed Quotes
DELL241213P167500
- 0.00
- 0.000.00%
15min DelayClose Dec 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest167.50Strike Price0.00Turnover0.00%IV-41.41%PremiumDec 13, 2024Expiry Date49.05Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.39Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Dell Technologies Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
7
1
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
+2
1
$Dell Technologies (DELL.US)$ for dell, 4 -5 dollars gain is not safe.. can dive 10-20 dollars anytimes
3
2
2
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
4
$Advanced Micro Devices (AMD.US)$ this should be no surprise that aipc's aren't as robust going into the fourth quarter and the reason is Dell told everybody this in their most recent quarter. the only soft area in all of Dell was personal computers. obviously AMD sells through to Dell and others so if Dell is weak and that segment then AMD is weak also and this is one of the reasons why I said AMD is a shit company. they're gaming and their PC business is underwhelming, so a big percentage of th...
6
2
2
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.